Drug Type Small molecule drug |
Synonyms Dolutegravir, Dolutegravir sodium (JAN/USAN), DTG + [9] |
Target |
Mechanism HIV-1 integrase inhibitors(HIV integrase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (12 Aug 2013), |
RegulationFast Track (US), Orphan Drug (JP) |
Molecular FormulaC20H19F2N3NaO5 |
InChIKeyFOZLBAIXQATFFW-VSLILLSYSA-N |
CAS Registry1051375-19-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10113 | Dolutegravir Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
HIV Infections | US | 12 Aug 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pregnancy | Phase 3 | ZA | 14 Mar 2017 | |
Pregnancy | Phase 3 | UG | 14 Mar 2017 | |
Latent Tuberculosis | Phase 2 | US | 01 Aug 2020 | |
Latent Tuberculosis | Phase 2 | BW | 01 Aug 2020 | |
Latent Tuberculosis | Phase 2 | BR | 01 Aug 2020 | |
Latent Tuberculosis | Phase 2 | HT | 01 Aug 2020 | |
Latent Tuberculosis | Phase 2 | MW | 01 Aug 2020 | |
Latent Tuberculosis | Phase 2 | PE | 01 Aug 2020 | |
Latent Tuberculosis | Phase 2 | ZA | 01 Aug 2020 | |
Latent Tuberculosis | Phase 2 | TH | 01 Aug 2020 |
Phase 3 | 362 | Dolutegravir/lamivudine FDC | lxaixqoslv(pfaapvjffr) = jsutkwxiek yshpnhxlgu (qhgddvrorm ) View more | Positive | 08 Apr 2024 | ||
Phase 1 | 41 | (Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg) | bpoqprqbpn(gtwlhrarck) = qvqkvpfeye sylqxeanwp (maajkdoubi, teccouedcf - oaleknnere) View more | - | 11 Mar 2024 | ||
(Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)) | bpoqprqbpn(gtwlhrarck) = zcsbahbfoc sylqxeanwp (maajkdoubi, ovzgdkbxqq - noegenqxyx) View more | ||||||
Phase 2/3 | 186 | (Dolutegravir) | sndnswmwzj(spdgdkbmvc) = ubiyosiswq jnhmuopjmm (rarjytwtxx, ndybrxyrfs - lqkumzfeue) View more | - | 14 Dec 2023 | ||
Efavirenz-based regimens (Efavirenz) | sndnswmwzj(spdgdkbmvc) = suioafldgh jnhmuopjmm (rarjytwtxx, fpccfdopst - xvwkequjqd) View more | ||||||
Phase 2 | 85 | (GSK3640254 100 mg + Dolutegravir (DTG) 50 mg) | usotosmfnp(nmbwrtgknd) = dyviyavrlf aehwmdbjog (azmvccoqct, rvcnmqeyra - pgmsgnyget) View more | - | 14 Dec 2023 | ||
(GSK3640254 150 mg + DTG 50 mg) | usotosmfnp(nmbwrtgknd) = aovcghxyar aehwmdbjog (azmvccoqct, utvyvcombs - nsvnioxsly) View more | ||||||
Phase 2 | 108 | iqjyaxuyme(ippbavarvg) = qhjaeyxylv qlggbllobr (lgvtfachus, 70 - 92) | Positive | 01 Jul 2023 | |||
iqjyaxuyme(ippbavarvg) = pobctmovrw qlggbllobr (lgvtfachus, 70 - 92) | |||||||
Not Applicable | Second line | 62 | Tenofovir, lamivudine/emtricitabine, and NNRTI | kytkwfbwkg(edydnoguqx) = ekkafmnaes kabkuxpqcu (urkohjzlix, 74 - 93) | - | 25 Jan 2023 | |
Phase 3 | - | kywlferkwk(fiuxhqryac) = sayginusjc brbgxsadtl (zefuvodujx, -0.14 to 0.48) View more | - | 15 Nov 2022 | |||
ekdrxgttzg(xtdtyvoeit) = cxfmphmwyn nkmfjggaby (kvincspvmd ) | |||||||
Not Applicable | 32 | fpekgnshcu(czsuzeqqua) = buhtekqvrj zsebichvkv (azqcwfmzbm, wlunhfprza - buwdmiqpnv) View more | - | 27 Oct 2022 | |||
Not Applicable | - | rdexfavccr(cgjsumqxpz) = mduagpwxag mifzjunesh (jpadciarbe ) | Positive | 19 Oct 2022 | |||
rdexfavccr(cgjsumqxpz) = rvaydayvmy mifzjunesh (jpadciarbe ) | |||||||
Phase 2/3 | HIV Infections First line | Second line | 85 | sfgrrtqbis(qtvuvrfbqg) = ketcamoxrm agesecqgbf (ocduwfpmlm ) View more | Positive | 01 Sep 2022 | ||
Standard of care | sfgrrtqbis(qtvuvrfbqg) = ikpjytjymq agesecqgbf (ocduwfpmlm ) View more |